Urethral cancer

Last updated

Urethral cancer
Urethral urothelial cell carcinoma.jpg
Micrograph of a urethral cancer, urothelial cell carcinoma, found on a prostate core biopsy. H&E stain.
Specialty Oncology Urology
Symptoms Blood in the urine, lump at end of penis, [1] Bloody urethral discharge. [2]

Urethral cancer is a rare cancer originating from the urethra. [1] The disease has been classified by the TNM staging system and the World Health Organization. [1] [3] [4]

Contents

Symptoms include blood in the urine, lump at end of penis, [1] or bloody penile discharge. [2]

Diagnosis is established by transurethral biopsy. [1]

The most common type is papillary urothelial carcinoma. [1] [5] Risk factors suggested include prolonged irritations of the urethra due to urinary catheterization, chronic inflammation due to infection, radiation, diverticula of the urethra, and urethral strictures. [1]

Signs and symptoms

Symptoms that may be caused by urethral cancer include:

Diagnosis

Diagnosis is established by transurethral biopsy and histological findings. [1] Bladder cystoscopy is performed to detect if there is simultaneous bladder cancer. [1]

Histology

Types of urethral cancer include the most common type urothelial carcinoma, and others including squamous cell carcinoma, and adenocarcinoma. Melanoma and sarcoma are rare. [1]

Staging

The World Health Organization classification of tumours of the urinary system and male genital organs (4th edn) was published in January 2016. [3] Urethral cancer has also been classified by the TNM staging system. [4]

TNM classification and 2016 WHO grading for primary urethral carcinoma [1] [3] [4]
T-categoryDescription
TXPrimary tumor cannot be assessed
T0No evidence of primary tumor
Urethra (male and female)
TaNoninvasive papillary, polypoid, or verrucous carcinoma
TisCarcinoma in situ
T1Tumor invades subepithelial connective tissue
T2Tumor invades any of the following: corpus spongiosum, prostate, periurethral muscle
T3Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, anterior vagina, bladder neck (extraprostatic extension)
T4Tumor invades other adjacent organs (invasion of the bladder)
Urothelial (transitional cell) carcinoma of the prostate
Tis puCarcinoma in situ, involvement of prostatic urethra
Tis pdCarcinoma in situ, involvement of prostatic ducts
T1Tumor invades subepithelial connective tissue (for tumors involving prostatic urethra only)
T2Tumor invades any of the following: prostatic stroma, corpus spongiosum, periurethral muscle
TaNoninvasive papillary, polypoid, or verrucous carcinoma
T3Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, bladder neck (extraprostatic extension)
T4Tumor invades other adjacent organs (invasion of the bladder or rectum)
N—regional lymph nodes
NXRegional lymph nodes cannot be assessed
N0No regional lymph node metastasis
N1Metastasis in a single lymph node
N2Metastasis in multiple lymph nodes
M—Distant Metastasis
M0No distant metastasis
M1Distant metastasis

Treatment

Surgery is the most common treatment for cancer of the urethra. [6] One of the following types of surgery may be done: Open excision, Electro-resection with flash, Laser surgery, Cystourethrectomy, Cystoprostatectomy, Anterior body cavity, or Incomplete or basic penectomy surgery.

Radiation therapy has also been used in some cases. [1]

Chemotherapy is sometimes used to destroy urethral cancer cells. It is a systemic urethral cancer treatment (i.e., destroys urethral cancer cells throughout the body) that is administered orally or intravenously. Medications are often used in combination to destroy urethral cancer that has metastasized. Commonly used drugs include cisplatin, vincristine, and methotrexate.[ clarification needed ]

Side effects include anemia (causing fatigue, weakness), nausea and vomiting, loss of appetite, hair loss, mouth sores, increased risk for infection, shortness of breath, or excessive bleeding and bruising. [7]

Epidemiology

Primary urethral cancer is rare and contributes to less than 1% of all cancers. It is three times more common in men than women and its incidence rises after the age of 75. [1]

Around half of affected people have locally advanced disease when they first present. [1] 54–65% of cases are of the urothelial carcinoma type. [1]

Prolonged irritations of the urethra due to urinary catheterization, chronic inflammation due to infection, radiation, diverticula of the urethra, and urethral strictures, may increase the risk of primary urethral cancer. [1] Other risk factors include squamous cell carcinoma (SCC) and genital lichen sclerosus. [1]

Prognosis

A study of the National Cancer Database in the United States assessed cases of primary urethral cancer from 2004 to 2013, finding that median survival was 49 months with 5- and 10-year survival rates estimated at 46% and 31% respectively. [8] A study of the RARECARE project, aimed at investigating rare cancers in Europe, estimated a 5-year relative survival rate of 54% in patients with cancer of the urethra. [9]

See also

Related Research Articles

<span class="mw-page-title-main">Urethra</span> Tube that connects the urinary bladder to the external urethral orifice

The urethra is a tube that connects the urinary bladder to the urinary meatus for the removal of urine from the body of both females and males. In human females and other primates, the urethra connects to the urinary meatus above the vagina.

<span class="mw-page-title-main">Bladder</span> Organ in humans and vertebrates that collects and stores urine from the kidneys before disposal

The bladder is a hollow organ in humans and other vertebrates that stores urine from the kidneys before disposal by urination. In humans, the bladder is a distensible organ that sits on the pelvic floor. Urine enters the bladder via the ureters and exits via the urethra. The typical adult human bladder will hold between 300 and 500 ml before the urge to empty occurs, but can hold considerably more.

<span class="mw-page-title-main">Prostate</span> Gland of the male reproductive system in most mammals

The prostate is both an accessory gland of the male reproductive system and a muscle-driven mechanical switch between urination and ejaculation. It is found in all male mammals. It differs between species anatomically, chemically, and physiologically. Anatomically, the prostate is found below the bladder, with the urethra passing through it. It is described in gross anatomy as consisting of lobes and in microanatomy by zone. It is surrounded by an elastic, fibromuscular capsule and contains glandular tissue, as well as connective tissue.

<span class="mw-page-title-main">Benign prostatic hyperplasia</span> Noncancerous increase in size of the prostate gland

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.

<span class="mw-page-title-main">Bladder cancer</span> Urinary system cancer that begins in the urinary bladder

Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. Symptoms include blood in the urine, pain with urination, and low back pain. It is caused when epithelial cells that line the bladder become malignant.

<span class="mw-page-title-main">Urethral stricture</span> Medical condition

A urethral stricture is a narrowing of the urethra, the tube connected to the bladder that allows the passing of urine. The narrowing reduces the flow of urine and makes it more difficult or even painful to empty the bladder.

Penile cancer, or penile carcinoma, is a cancer that develops in the skin or tissues of the penis. Symptoms may include abnormal growth, an ulcer or sore on the skin of the penis, and bleeding or foul smelling discharge.

<span class="mw-page-title-main">Kidney cancer</span> Medical condition

Kidney cancer, also known as renal cancer, is a group of cancers that starts in the kidney. Symptoms may include blood in the urine, a lump in the abdomen, or back pain. Fever, weight loss, and tiredness may also occur. Complications can include spread to the lungs or brain.

<span class="mw-page-title-main">Hematuria</span> Medical condition

Hematuria or haematuria is defined as the presence of blood or red blood cells in the urine. "Gross hematuria" occurs when urine appears red, brown, or tea-colored due to the presence of blood. Hematuria may also be subtle and only detectable with a microscope or laboratory test. Blood that enters and mixes with the urine can come from any location within the urinary system, including the kidney, ureter, urinary bladder, urethra, and in men, the prostate. Common causes of hematuria include urinary tract infection (UTI), kidney stones, viral illness, trauma, bladder cancer, and exercise. These causes are grouped into glomerular and non-glomerular causes, depending on the involvement of the glomerulus of the kidney. But not all red urine is hematuria. Other substances such as certain medications and foods can cause urine to appear red. Menstruation in women may also cause the appearance of hematuria and may result in a positive urine dipstick test for hematuria. A urine dipstick test may also give an incorrect positive result for hematuria if there are other substances in the urine such as myoglobin, a protein excreted into urine during rhabdomyolysis. A positive urine dipstick test should be confirmed with microscopy, where hematuria is defined by three or more red blood cells per high power field. When hematuria is detected, a thorough history and physical examination with appropriate further evaluation can help determine the underlying cause.

<span class="mw-page-title-main">Urinary retention</span> Inability to completely empty the bladder

Urinary retention is an inability to completely empty the bladder. Onset can be sudden or gradual. When of sudden onset, symptoms include an inability to urinate and lower abdominal pain. When of gradual onset, symptoms may include loss of bladder control, mild lower abdominal pain, and a weak urine stream. Those with long-term problems are at risk of urinary tract infections.

<span class="mw-page-title-main">Transurethral resection of the prostate</span> Surgical procedure to perform a prostatectomy

Transurethral resection of the prostate is a urological operation. It is used to treat benign prostatic hyperplasia (BPH). As the name indicates, it is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection. It has been the standard treatment for BPH for many years, but recently alternative, minimally invasive techniques have become available. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. The outcome is considered excellent for 80–90% of BPH patients. The procedure carries minimal risk for erectile dysfunction, moderate risk for bleeding, and a large risk for retrograde ejaculation.

<span class="mw-page-title-main">Transitional epithelium</span> A type of tissue

Transitional epithelium is a type of stratified epithelium. Transitional epithelium is a type of tissue that changes shape in response to stretching. The transitional epithelium usually appears cuboidal when relaxed and squamous when stretched. This tissue consists of multiple layers of epithelial cells which can contract and expand in order to adapt to the degree of distension needed. Transitional epithelium lines the organs of the urinary system and is known here as urothelium. The bladder, for example, has a need for great distension.

<span class="mw-page-title-main">Posterior urethral valve</span> Medical condition

Posterior urethral valve (PUV) disorder is an obstructive developmental anomaly in the urethra and genitourinary system of male newborns. A posterior urethral valve is an obstructing membrane in the posterior male urethra as a result of abnormal in utero development. It is the most common cause of bladder outlet obstruction in male newborns. The disorder varies in degree, with mild cases presenting late due to milder symptoms. More severe cases can have renal and respiratory failure from lung underdevelopment as result of low amniotic fluid volumes, requiring intensive care and close monitoring. It occurs in about one in 8,000 babies.

<span class="mw-page-title-main">Transitional cell carcinoma</span> Medical condition

Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs in the urinary system. It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. Symptoms of urothelial carcinoma in the bladder include hematuria. Diagnosis includes urine analysis and imaging of the urinary tract (cystoscopy). Transitional cell carcinomas arise from the transitional epithelium, a tissue lining the inner surface of these hollow organs. When the term "urothelial" is used, it specifically refers to a carcinoma of the urothelium, meaning a transitional cell carcinomas of the urinary system.

<span class="mw-page-title-main">Prostatic stent</span>

A prostatic stent is a stent used to keep open the male urethra and allow the passing of urine in cases of prostatic obstruction and lower urinary tract symptoms (LUTS). Prostatic obstruction is a common condition with a variety of causes. Benign prostatic hyperplasia (BPH) is the most common cause, but obstruction may also occur acutely after treatment for BPH such as transurethral needle ablation of the prostate (TUNA), transurethral resection of the prostate (TURP), transurethral microwave thermotherapy (TUMT), prostate cancer or after radiation therapy.

Lower urinary tract symptoms (LUTS) refer to a group of clinical symptoms involving the bladder, urinary sphincter, urethra and, in men, the prostate. The term is more commonly applied to men—over 40% of older men are affected—but lower urinary tract symptoms also affect women. The condition is also termed prostatism in men, but LUTS is preferred.

Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship based interventions. These interventions are focused on five domains including: physical symptoms, psychological symptoms, surveillance, health promotion and care coordination. However, a published review has found only high levels of evidence for interventions that target physical and psychological symptom management and health promotion, with no reviews of interventions for either care coordination or surveillance. The favored treatment option depends on the stage of the disease, the Gleason score, and the PSA level. Other important factors include the man's age, his general health, and his feelings about potential treatments and their possible side-effects. Because all treatments can have significant side-effects, such as erectile dysfunction and urinary incontinence, treatment discussions often focus on balancing the goals of therapy with the risks of lifestyle alterations.

<span class="mw-page-title-main">Ureteral cancer</span> Medical condition

Ureteral cancer is cancer of the ureters, muscular tubes that propel urine from the kidneys to the urinary bladder. It is also known as ureter cancer, renal pelvic cancer, and rarely ureteric cancer or uretal cancer. Cancer in this location is rare. Ureteral cancer becomes more likely in older adults, usually ages 70–80, who have previously been diagnosed with bladder cancer.

A urethral diverticulum is a condition where the urethra or the periurethral glands push into the connective tissue layers (fascia) that surround it.

<span class="mw-page-title-main">Surgery for benign prostatic hyperplasia</span> Type of surgery

If medical treatment is not effective, surgery may need to be performed for benign prostatic hyperplasia.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Janisch, Florian; Abufaraj, Mohammad; Fajkovic, Harun; Kimura, Shoji; Iwata, Takehiro; Nyirady, Peter; Rink, Michael; Shariat, Shahrokh F. (1 September 2019). "Current Disease Management of Primary Urethral Carcinoma". European Urology Focus. 5 (5): 722–734. doi: 10.1016/j.euf.2019.07.001 . ISSN   2405-4569. PMID   31307949.
  2. 1 2 3 Kahan, Scott; Miller, Redonda; Smith, Ellen G. (2008). "126. Penile Discharge". Signs and Symptoms. Lippincott Williams & Wilkins. ISBN   978-0-7817-7043-9.
  3. 1 2 3 Compérat, Eva; Varinot, Justine (2016). "Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization classification" . Histopathology. 69 (5): 717–726. doi:10.1111/his.13025. ISSN   1365-2559. PMID   27353436. S2CID   24816719.
  4. 1 2 3 Brierley, James D.; Gospodarowicz, Mary K.; Wittekind, Christian (2017). "Urological Tumours". TNM Classification of Malignant Tumours (8th ed.). John Wiley & Sons. p. 208. ISBN   978-1-119-26354-8.
  5. Ries, LAG; Young, JL; Keel, GE; Eisner, MP; Lin, YD; Horner, M-J, eds. (2007). "Chapter 30: Cancers of Rare Sites". SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988–2001, Patient and Tumor Characteristics. SEER Program. Vol. NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute. pp. 251–262. Archived from the original on 10 October 2013. Retrieved 18 October 2013.
  6. Pagliaro, Lance (28 June 2016). Rare Genitourinary Tumors. Springer. p. 157. ISBN   978-3-319-30046-7.
  7. Urethral Cancer Treatment
  8. Sui W, RoyChoudhury A, Wenske S, Decastro GJ, McKiernan JM, Anderson CB (2017). "Outcomes and Prognostic Factors of Primary Urethral Cancer". Urology. 100: 180–186. doi:10.1016/j.urology.2016.09.042. PMID   27720774.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. Visser O, Adolfsson J, Rossi S, Verne J, Gatta G, Maffezzini M; et al. (2012). "Incidence and survival of rare urogenital cancers in Europe". Eur J Cancer. 48 (4): 456–64. doi:10.1016/j.ejca.2011.10.031. PMID   22119351.{{cite journal}}: CS1 maint: multiple names: authors list (link)